B6;129-Scn10atm3(cre/ERT2)Jwo/H
Status | Available to order |
EMMA ID | EM:02603 |
International strain name | B6;129-Scn10atm3(cre/ERT2)Jwo/H |
Alternative name | Nav1.8-CreERT2 |
Strain type | Targeted Mutant Strains : Knock-in |
Allele/Transgene symbol | Scn10atm3(cre/ERT2)Jwo, |
Gene/Transgene symbol | Scn10a |
Information from provider
Provider | John Wood |
Provider affiliation | University College Lonodon |
Genetic information | The creERT2 gene was inserted at the endogenous ATG start site of the mouse Scn10a (Nav1.8) gene. This strain expresses the tamoxifen-inducible creERT2 recombinase in Scn10a (Nav1.8)-positive neurons in dorsal root ganglia. |
Phenotypic information | None observed. Heterozygous Scn10a (Nav1.8)-creERT2 can express enough cre recombinase to delete the floxed fragment, but it does not affect the expression of Scn10a in Scn10a-positive neurons in dorsal root ganglion. |
Breeding history | Mostly C57BL/6; between 3-4 crossings to C57BL/6. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | no |
Immunocompromised | no |
Information from EMMA
Archiving centre | Mary Lyon Centre at MRC Harwell, Oxford, United Kingdom |
Animals used for archiving | heterozygous C57BL/6 |
Breeding at archiving centre | Males were archived upon arrival at the archiving centre. No breeding was performed. |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Romano-Ward syndrome / Orphanet_101016
- Sodium channelopathy-related small fiber neuropathy / Orphanet_306577
Literature references
- Tamoxifen-inducible NaV1.8-CreERT2 recombinase activity in nociceptive neurons of dorsal root ganglia.;Zhao Jing, Nassar Mohammed A, Gavazzi Isabella, Wood John N, ;2006;Genesis (New York, N.Y. : 2000);44;364-71; 16850455
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).